Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01970254|
Recruitment Status : Recruiting
First Posted : October 28, 2013
Last Update Posted : January 8, 2018
|Condition or disease||Intervention/treatment|
|Cancer Hepatitis B HBV||Other: HBV screening tests Behavioral: HBV risk assessment survey|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||3441 participants|
|Official Title:||Widespread Versus Selective Screening for Hepatitis B Infection Prior to Chemotherapy|
|Study Start Date :||June 2013|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||December 2019|
Hepatitis B Screening
Testing for positive hepatitis B virus (HBV) infection before chemotherapy using three HBV screening tests (HBsAg,anti-HBc,and anti-HBs) and survey completion.
Other: HBV screening tests
Three (3) hepatitis B virus (HBV) infection tests: HBsAg, anti-HBc, and anti-HBsBehavioral: HBV risk assessment survey
Estimated time to complete the HBV risk assessment tool is 5 minutes.
Other Name: Questionnaire
- Rate of a positive result (HBsAg, anti-HBc, and anti-HBs) before first chemotherapy [ Time Frame: Baseline blood tests, approximately 30 minutes for blood draw ]Number of screened participants (new cancer patients undergoing chemotherapy) with positive hepatitis B virus (HBV) infection compared to total screened. Prospective, universal screening of eligible MD Anderson cancer patients not known to have HBV infection using three HBV screening tests (HBsAg,anti-HBc,and anti-HBs) prior to chemotherapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01970254
|Contact: Jessica P. Hwang, MD||713-745-4516|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator: Jessica P. Hwang, MD|
|Study Chair:||Jessica P. Hwang, MD||M.D. Anderson Cancer Center|